NSCLC market projected to reach $14.6 billion by 2024

Following the recent spate of approvals in both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), the treatment landscape is becoming increasingly difficult to navigate for both physicians and patients, highlighting the need for better education, access, and infrastructure to support physicians’ and patients’ choices of the optimal therapies.

Data and analytics company GlobalData expects the global NSCLC market to be worth $14.6 billion by 2024, over six-fold more than the SCLC market, which is expected to reach only $2.3 billion in the same timeframe.

Francesca Blum, UK oncology director at GlobalData, comments: “As SCLC and NSCLC both have more than twenty immunotherapy products currently in Phase II or III development, treatment paradigms for both forms of the disease will become increasingly complex, requiring treatments to be chosen from a growing selection of similar options.”